ASH 2022 | GEM2014MAIN: assessing MRD with NGF in bone marrow and MS in peripheral blood in multiple myeloma
Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, provides an overview of a measurable residual disease (MRD) analysis of the Phase III GEM2014MAIN trial (NCT02406144). MRD was assessed in bone marrow with next-generation flow (NGF) and in peripheral blood with quantitative immunoprecipitation mass-spectrometry (QIP-MS). The two MRD assessment techniques were found to be comparable and did not have an additive value. Consistent MRD negativity over a two-year period was found to correlate with positive survival outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene: Honoraria, Speakers Bureau; Amgen, Celgene, Takeda and The Binding Site: Honoraria; Celgene, Janssen, Amgen and Takeda: Research Funding; Amgen, Celgene, Janssen and Takeda: Consultancy.
